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Pharmacogenomics 
Antidepressant Dosing in Major Depression: 
A Pharmacogenomic Approach 
Morgan Homan, Haval Norman, Victoria Cho, YousifRojeab, Ph.D. 
Abstract 
Major depressive disorder (MDD) is the most predominant 
mental disorder in the United States, with serious and costly 
health risks if not successfully managed. Pharmacotherapy is 
a standard option for MDD treatment, but patients often re-
quire extensive therapy adjustments to find a suitable regi-
men. Pharmacogenomics may enable greater precision in 
antidepressant therapy. Genotypic variations in CYP2D6 and 
CYP2C19 metabolic enzymes are reliable predictors of serum 
drug concentration, but the complex dose-response relation-
ship of antidepressants prevents such variations from pre-
dicting therapy success. Additionally, ABCBl has been exam-
ined for its role in P-glycoprotein efflux of antidepressants in 
the brain, yet it is still inconclusive as to which variations are 
correlated with drug response. Current genotypic guidelines 
are largely proactive and clinical trials utilizing genotypic 
dosing have shown significant reductions in side effects and 
health care costs. Further studies of genotypic targets are 
needed and, if the possible clinical benefits are confirmed, 
the use of genotyping will be an important tool in optimizing 
antidepressant therapy. 
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Depression Background 
The National Institute of Mental Health (NIMH) defines ma-
jor depressive disorder (MOD) as "severe symptoms that in-
terfere with your ability to work, sleep, study, eat and enjoy 
life. An episode may occur only once in a person's lifetime, but 
more often a person has several episodes."1 Depression can be 
caused by a multitude of factors, a few of which include envi-
ronmental, genetic, psychological and biological influences. 
Patients with MOD typically experience a low quality of life.2 
Often, depressed patients experience a decrease in physical, 
social and role functioning more than individuals with other 
chronic conditions such as diabetes or osteoarthritis. Patients 
with MDD often report poor intimate relationships, poor social 
interactions and social irritability. These individuals typically 
have a greater household or financial strain as well. It is also 
common for depression patients to experience limitations in 
the workplace, exhibit poor overall health and have a higher 
level of missed days of work. 
Major depressive disorder is the most prevalent mental 
health disorder in the United States.3 It is estimated that 6.7 
percent of adults in the United States experienced a major 
depressive episode in 2014. The female population was more 
likely to experience these episodes (8.2 percent) versus the 
male population ( 4.8 percent). Major depressive episodes 
were also more prevalent in adults aged 18 to 25 years (9.3 
percent) compared to adults aged 26 to 49 years (7.2 per-
cent) and those aged 50 years and older (5.2 percent). The 
prevalence of MOD was even greater in adolescents aged 12 
to 17 years (11.4 percent) than in adults in 2014. In this ado-
lescent age group, the female population was also more likely 
to experience a major depressive episode (17.3 percent) than 
males (5.7 percent). Prevalence in adolescents increased 
with age. Twelve-year-olds had a prevalence of 5. 7 percent 
while 17-year-olds had a prevalence of 15.1 percent. 
While MOD varies between patients, the NIMH identifies sev-
eral signs and symptoms that may indicate the onset of de-
pression.1 A few of these include feelings of hopelessness, 
pessimism, guilt, worthlessness, fatigue, decreased energy, 
insomnia and persistent sad, anxious or empty feelings. A 
depressed patient may also experience thoughts of suicide, 
have difficulty concentrating, making decisions and remem-
bering details. 
The diagnosis criteria for MOD has been described by the 
American Psychiatric Association (APA) in the fifth edition of 
the Diagnostic and Statistic Manual of Mental Disorders 
(DSM-5).4 The diagnosis criteria are summarized in Table 1. 
It is important to note that an individual responding to a sig-
nificant loss, such as financial or loss of a loved one, may ex-
hibit some of the criteria specified in section A of Table 1; 
therefore, the medical professional's clinical judgment must 
be exercised to determine if this constitutes a major depres-
sive episode. 
Upon diagnosis of MOD, the APA recommends psychiatric 
management which includes establishing and maintaining a 
therapeutic alliance.s The patient should undergo a 
psychiatric assessment and be evaluated for safety, function-
al impairment and quality of life. The patient's care should be 
coordinated with other clinicians, and his or her psychiatric 
status should be monitored. The health care team should 
integrate measurements into psychiatric management, assist 
with treatment adherence and provide education to the 
patient and the family. 
The acute phase of MOD treatment begins with the initiation 
of treatments This often constitutes the introduction of phar-
macotherapy but may also include depression-focused psy-
chotherapy, a combination of the two, electroconvulsive 
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Table 1. Diagnostic Criteria of Major Depressive Disorder (MDD).4 
A. The patient must demonstrate at least five of the following symptoms, which must have been present almost every day 
during a consecutive 14-day period. It is important to point out that these symptoms must demonstrate a change from 
the patient's normal functioning. These symptoms may be given as a subjective report or as observed by others. Several 
of the diagnosis criteria may present differently in children as noted below. 
The patient must • Depressed mood for the majority of the day. (Note: In children and adolescents, may 
demonstrate at least one present as irritable mood.) 
of the following. 
• Noticeably decreased interest or pleasure in all, or nearly all, activities for the majority 
of the day. 
The patient must • Notable weight loss when not attempting to diet or weight gain or change in appetite. 
demonstrate at least four (Note: In children, may present as failure to make expected weight gain.) 
of the following. 
• Insomnia or hypersomnia. 
• Psychomotor agitation or retardation (this criterion must be noted by others and not 
solely based on subjective feelings of the patient of uneasiness or being slowed down). 
• Fatigue or lack of energy. 
• Feelings of inadequacy or excessive or inappropriate guilt (which may be deranged), 
not solely self-blame or guilty feelings about being sick. 
• Decreased ability to think, concentrate or make decisions. 
• Frequent thoughts of death that expand beyond fear of dying, periodic suicidal 
thoughts without a definitive plan, a suicide attempt or a definitive plan for committing 
suicide. 
B. The symptoms must cause a significant distress or impairment in normal daily functions such as social, occupational or 
other important areas of operation. 
c. The symptoms exhibited must not be attributed to any other factor such as the psychological effects of a substance or a 
symptom of another medical condition. 
D. The major depressive episode as expressed above must not be better attributed to a psychotic disorder, including schiz-
ophrenic disorders. 
E. The patient must not have experienced a manic or hypomanic episode. The exception to this criterion is ifthe episode 
can be attributed to another medical condition. 
Adapted from: American Psychiatric Association: Desk Reference to the Diagnostic Criteria from DSM-5. Arlington (VA): American Psychiat-
ric Association; 2013. Major Depressive Disorder; p. 94-95. 
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light therapy. For patients with mild to moderate MOD, the 
APA recommends an antidepressant as initial treatment. In 
individuals with severe MOD, the APA deems an antidepres-
sant necessary for treatment unless the patient plans to 
undergo ECT. The medications initially recommended for 
depression patients include selective serotonin reuptake in-
hibitors (SSRls), serotonin norepinephrine reuptake inhibi-
tors (SNR!s ), mirtazapine, or bupropion. The individual 
agent, however, may be chosen based on anticipated side 
effects, patient's ability to tolerate the drug, safety considera-
tions targeted to the individual patient and pharmacologic 
properties of the drug itself. These properties include the 
half-life, drug-drug interactions and the drug's action on cy-
tochrome P (CYP) 450 enzymes. Monoamine oxidase inhibi-
tors (MAO!s) are typically reserved for patients who do not 
respond to first-line treatments. 
Careful monitoring should occur during the acute phase, and 
dosage or drug modifications should be made based on side 
effects or adverse events.s When assessing the efficacy of an 
agent in a particular patient, the medication should be dis-
continued after one month if the patient shows no signs of 
symptomatic improvement. If a patient is unresponsive or 
only partially responsive after four to eight weeks, the drug 
and dose should be adjusted and reevaluated in another four 
to eight weeks. When adjustments are necessary, the dose is 
titrated first as long as the patient has not experienced any 
adverse events and the side effects are well-tolerated. If a 
dose adjustment does not demonstrate any improvement, 
the patient may be prescribed a different medication either 
from the same class or another class of antidepressants. A 
patient is considered to be in the acute phase of treatment 
until he or she has demonstrated a response to medication. A 
response may not appear with the first treatment choice, so 
the acute phase is not limited to a specific time frame and 
may continue for an extended period of time. 
Once a patient has demonstrated some success with an agent 
in the acute phase, he or she moves on to the continuation 
phase.s Here, the patient is monitored for potential relapse 
while on the medication initiated with success in the acute 
phase. This drug is typically continued for four to nine 
months, and the APA recommends depression-focused psy-
chotherapy for prevention of relapse. A patient may move 
onto the maintenance phase of therapy using the same agent 
he or she used in the acute and continuation phases with suc-
cess, but the medication may be adjusted to a full therapeutic 
dose. The maintenance phase is strongly recommended for 
patients who have high risk factors for recurrence of a major 
depressive episode. These risk factors may include family 
history of depression or mood disorders, presence of psycho-
social triggers or appearance of lingering symptoms. Mainte-
nance treatment continues indefinitely unless a patient and 
physician come to the decision to discontinue treatment. If 
pharmacologic treatment is discontinued, the dose should be 
tapered to prevent relapse and discontinuation symptoms. 
The patient should also be counseled on the signs of a re-
lapse and have a plan in place if such an incident occurs. 
Monitoring of the patient should continue for several months 
after discontinuation. 
While there are many options for initiating antidepressant 
therapy, adverse effects and poor efficacy often lead to a 
game of trial and error. This can waste money and time on an 
ineffective agent. It often takes at least one month to deter-
mine if the chosen treatment will be successful in a particular 
patient, so it may take months to years for a patient to find 
the right medication in the acute treatment phase to control 
his or her MOD. Genomic testing can help determine how a 
patient will react pharmacokinetically and pharmacodynami-
cally to a particular drug and increase the likelihood of 
choosing an effective drug therapy at the initiation of treat-
ment. 
CYP2D6 and CYP2C19 PK/PG 
The CYP2D6 and CYP2C19 genes code for members of the 
CYP450 liver enzymes, which are heavily involved in the me-
tabolism of many antidepressant medications.6.7 CYP206 
metabolism influences clearance of the SSRis fluvoxamine 
and paroxetine and, also, tricyclic antidepressants (TCAs) 
such as amitriptyline, clomipramine, desipramine, imipra-
mine, nortriptyline and trimipramine. CYP2Cl 9 metabolism 
is observed with SSRis including citalopram, escitalopram 
and sertraline, as well as TCAs like amitriptyline, clomipra-
mine, imipramine and trimipramine. 
Both CYP2D6 and CYP2C19 have numerous polymorphisms 
in the population, with some alleles coding for decreased or 
increased activity compared to the standard function seen in 
the most common genotypes.6,7 Combinations of these alleles 
result in several phenotypic classes: poor, intermediate, 
extensive and ultrarapid metabolizers. Two of the primary 
concerns are that poor metabolizers build up higher plasma 
concentrations of antidepressants and may be at greater risk 
of toxicities and side effects, while ultrarapid metabolizers 
may be more likely to experience treatment failure if plasma 
concentrations are too low. Pharmacogenomic guidelines 
have been developed and published for many SSRis and TCAs 
to adjust dosage or recommend alternative therapies. How-
ever, the clinical significance for these guidelines is still being 
debated and is additionally complicated by an uncertain dose 
-response relationship of antidepressant medications. 
A pair of studies by Hodgson and colleagues with infor-
mation from the Genome-Based Therapeutic Drugs for De-
pression Project (GENDEP) questioned the association of 
pharmacogenomic dosing and SSRI/TCA side effects and 
treatment response.B.9 The first study examined 223 patients 
on escitalopram and 161 patients on nortriptyline using a 
pragmatic design and flexible dosing protocol, where serum 
antidepressant concentration was assessed 8 weeks after 
treatment.8 Patients were additionally genotyped. Variation 
in CYP2C19 significantly correlated with escitalopram con-
centration (p=9.35*10-9), while CYP2D6 genotype was signifi-
cantly associated with nortriptyline levels (p=l.90*10-6). 
Neither genotyping nor serum concentration was significant-
ly related to treatment response for either medication. The 
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second study examined the connection between CYP450 gen-
otype and side effects with escitalopram and nortriptyline.9 
No significant association was found between genotype and 
side effects; serum concentration significantly predicted only 
a few minor effects, including the risk of dry mouth (p= 
0.0107), diarrhea (p=4.96*10-4) and dizziness (p=3.28*10·5) 
with escitalopram, and dry mouth (p=0.0331) with nortrip-
tyline. The authors acknowledged possible bias from the 
pragmatic design and flexible dosing, recognizing limited 
application of the results and the need for further study. This 
study demonstrates, again, that CYP genotyping is ineffective 
for predicting patient response. 
ABCB1PK/PG 
The ABCBl gene codes for the amino acid transporter 
P-glycoprotein (P-gp) in many organs, including brain capil-
lary endothelial cells where it drives out substrates and helps 
maintain the blood-brain barrier (BBB).10 Many drug classes, 
including the TCAs, SSRis and SNRI venlafaxine are substrates 
for P-gp and have limited uptake into the brain because of this 
efflux activity. Because of this limitation, genetic variation in 
ABCBl could result in altered P-gp function and clinically sig-
nificant changes in antidepressant distribution to the brain. 
A 2015 meta-analysis by Breitenstein and colleagues exam-
ined 16 pharmacogenetic studies associating ABCBl variants 
and antidepressant outcomes for MOD patients (n = 2,695).10 
A total of six single nucleotide polymorphisms (SNPs) were 
separately analyzed based on all studies, inpatient samples, 
outpatient samples, Caucasian only samples and without co-
medication sub-groups. The SNP rs2032583 was associ2ted 
with treatment outcomes across all studies (p = 0.035) and 
among all inpatient subjects (p = 1.5*10-5), while SNP 
rs2235015 was associated with treatment outcomes only 
among all inpatient subjects (p = 3.0*10·4). Both of those 
SNPs were intronic, meaning they did not alter the protein 
structure of P-gp but may modify brain delivery of antide-
pressants through unknown mechanisms. It was noted that 
the majority of the studies included did not have fixed dosag-
es but were adjusted based on patient condition. If drug dos-
es were decreased because of side effects, P-gp activity and 
BBB penetration may have been reduced and remain unde-
tected. 
Schatzberg and colleagues genotyped 10 ABCBl SNPs in 683 
MOD patients, including all six SNPs analyzed in the Breit-
enstein meta-analysis.11 Patients were randomized to treat-
ment with escitalopram, sertraline or venlafaxine ER for at 
least two weeks (576 subjects completed eight weeks of 
therapy), with treatment efficacy assessed by the 16-item 
Quick Inventory of Depressive Symptomatology- Self Rated 
(QIDS-SR). Only SNP rs10245483 was significantly associat-
ed with prediction of remission (Wald statistic W=12.64, 
p<0.001, odds ratio OR=3.48). Common allele (G) homozy-
gotes had significantly better response to escitalopram 
(p=0.032) and sertraline (p=0.020) than minor (T) allele 
homozygotes, which had significantly better response to 
venlafaxine (p=0.018); heterozygote genotypes had no signif-
icant differences across treatment. Similarly, major allele 
carriers had less adverse effects with escitalopram (p=0.037) 
while venlafaxine was associated with fewer side effects in 
minor allele homozygotes (p=0.017). The T minor allele has 
been reported to cause higher P-gp expression and may 
cause increased SSRI clearance, causing the observed, de-
creased efficacy. Venlafaxine activity as an SNRI may explain 
why it was more effective with minor alleles. The researchers 
acknowledged limitations in that serum drug concentrations 
were not collected and how as a pragmatic study the dosages 
were slightly lower than traditionally used in clinical drug 
trials, which could have altered response. 
Clinical Applications 
While pharmacogenomic data continue to be collected, many 
challenges remain in identifying factors significant to treat-
ment outcomes. In addition to the studies specifically exam-
ining the genes coding for CYP enzymes or P-gp transporters, 
several genome-wide association studies have attempted to 
detect genetic variations connected with antidepressant out-
come in MOD. The three largest were the GENDEP project, 
the Munich Antidepressant Response Signature (MARS) pro-
ject and the Sequenced Treatment Alternatives to Relieve 
Depression (STAR*D) study.12 A meta-analysis of data by the 
investigators of the three studies, including 2,256 subjects of 
Northern European descent with MOD, tested 1.2 million 
SNPs for association with symptom reduction and remission 
for up to 12 weeks of antidepressant therapy. No individual 
variant met significance criteria in the main analysis, sug-
gesting antidepressant success to be likely due to numerous 
minor genetic effects instead of one primary pathway. How-
ever, the analysis was limited by the absence of placebo 
groups in any of the three studies as well as by the heteroge-
neity of the trials, and the authors concluded that larger co-
horts of systemically treated and observed subjects were 
needed to conclusively test the approach. 
Despite the inability to precisely identify the genetic regions 
associated with antidepressant response, there is some evi-
dence suggesting genotypic-dosing may be a cost-effective 
tool in antidepressant treatment dosing. A one-year retro-
spective study of antidepressant therapy was conducted by 
Winner and colleagues in 2013, where 96 depressive or anxi-
ety disorder subjects were tested for CYP2D6, CYP2Cl 9, 
CYP2C9, CYP1A2, SLC6A4 and 5HTR2A genotypes.12 Subjects 
had their medication and genotype combinations categorized 
as "red-bin," "yellow-bin" or "green-bin" based on the degree 
of caution and monitoring required as developed by the As-
sureRx Health GeneSight, a genotype interpretive report.13 
Nine subjects were categorized as red bin, with 48 yellow 
and 39 green. Compared to the green or yellow bin, subjects 
with a medication in the red bin had 69 percent more total 
health care visits during the year (p= 0.014). Also, nonpsy-
chiatric medical visits were 67 percent higher for the red bin 
(p= 0.039). While red bin assignment was associated with 
greater numbers of psychiatric medications, there was no 
correlation between the number of drugs taken and any of 
the dependent measures, suggesting increase in health care 
utilization was directly related to red bin status. The authors 
concluded that pharmacogenomic information can better 
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as decrease costs. 
fied by medication prescribed or genetic profile, so extrapo-
lation of findings to specific drugs or polymorphisms is not 
possible. 
Genotypic Guidelines 
A 2015 study by Singh and colleagues provided buccal swabs 
for DNA analysis to 148 subjects with MOD, but only half 
were randomized to genotypic testing for CYP2D6, CYP2C19 
and ABCBl polymorphisms with dosing guided by the re-
sults.14 Remission rates were assessed by the Hamilton De-
pression Rating Scale (HORS) every four weeks for 12 weeks, 
with rating blinded to treatment groups. Remission from 
MOD was 2.52 times more likely with the guided treatment 
(95 percent confidence interval (Cl): 1.71-3.73, p<0.0001), 
while the unguided group was 1.13 times more likely to 
experience treatment intolerability issues (95 percent Cl: 
1.01-1.25; p=0.0272). The guided group also had significant-
ly lower risk of requiring sick leave ( 4 percent versus 15 per-
cent, p=0.0272) and shorter length of leave (4.3 days versus 
7.7 days, p=0.014). However, the trial results were not strati-
There are currently no dosing guidelines for ABCBl geno-
types, but the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) has published guidelines for SSR!s and 
TCAs based on CYP2D6 and CYP2C19 genotypes.7,s Their rec-
ommendations are compiled in Table 2 and Table 3. 
Conclusion 
Major depressive disorder is one of the most common mental 
illnesses in the United States. A large range of therapeutic 
options, significant adverse effects and a complex 
dose-response relationship contribute to the uncertainty in 
optimizing antidepressant therapy. Pharmacogenomics has 
attempted to explain some of the variability observed, but 
Table 2. CYP2D6 Phenotypic Guidelines for Antidepressant Drugs.6,7 
Drug Poor Metabolizers Intermediate Extensive Ultra-rapid 
Metabolizers Metabolizers Metabolizers 
TCAs: *4/*4,*4/*5,*5/*5,*4/*6 *4/*10, *5/*41 *1/*1,*1/*2,*2/*2, *lj*lxN, *lj*2xN 
Amitriptyline, Avoid due to potential for Consider 25% *1/*41, *l/*4, *2/*5, Avoid due to potential 
Nortriptyline, side effects, consider reduction of *10/*10 lack of efficacy, 
Clomipramine, alternatives not metabo- recommended Initiate therapy consider alternatives 
Desipramine, lized by CYP2D6. If used, starting dose (M). with recommended not metabolized by 
Imipramine, consider 50% reduction of starting dose (S). CYP2D6. !fused, 
Trimipramine recommended starting consider increasing 
dose (S). starting dose (S). 
Fluvoxamine *3/*4,*4/*4, *5/*5, *5/*6 *4/*10,*4/*41, *5/*9 *1/*l,*1/*2,*1/*4, *lf*lxN, *lf*2xN, *2/ 
Consider a 25-50% Initiate therapy *1/*5, *1/*9, *1/*41, *2xN 
reduction of with recommended *2/*2,*41/*41 No recommendation 
recommended starting starting dose (M). Initiate therapy with due to lack of evidence 
dose or use an alternative recommended (0). 
drug not metabolized by starting dose (S). 
CYP2D6 (0). 
Paroxetine *3/*4,*4/*4, *5/*5, *5/*6 *4/*10,*4/*41, *5/*9 *1/*l,*1/*2,*1/*4, *1/*lxN, *1/*2xN, *2/ 
Select alternative drug not Initiate therapy *1/*5,*1/*9,*1/*41, *2xN 
metabolized by CYP2D6, with recommended *2/*2,*41/*41 Select alternative drug 
or consider a 50% starting dose (M). Initiate therapy with not metabolized by 
reduction of recommended CYP2D6 (SJ. 
recommended starting starting dose (S). 
dose (0). 
Recommendation strength: S-strong, M-moderate, W-weak, 0-optional 
Adapted with permission from John Wiley and Sons, Inc., from Hicks et al. Clin Pharmacol Ther. 2013 May;93(5):402-8.© 2013 American 
Society for Clinical Pharmacology and Therapeutics. 
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Table 3. CYP2C19 Phenotypic Guidelines for Antidepressant Drugs.6•7 
Drug Poor Metabolizers Intermediate Extensive Ultra-rapid Metabolize rs Metabolize rs Metabolfzers 
SSRis: *2/*2,*2/*3,*3/*3 *1/*2,*1/*3,*2/*17 *1/*1 *17 /*17, *1/*17 
Citalopram, Consider a 50% reduction Initiate therapy with Initiate therapy with Initiate therapy with 
Escitalopram, of starting dose or select recommended start- recommended recommended 
Sertraline alternative drug not ing dose (S). starting dose (S). starting dose, 
metabolized by CYP2C19 consider alternative 
(M). drug not 
metabolized by 
CYP2C19 (M). 
TCAs: *2/*2,*2/*3,*3/*3 *1/*2,*1/*3,*2/*17 *1/*1 *17 /*17, *1/*17 
Amitriptyline, Consider a 50% reduction Initiate therapy with Initiate therapy with Initiate therapy with 
Clomipramine, of recommended starting recommended start- recommended recommended 
Imipramine, dose or select alternative ing dose (S). starting dose (S). starting dose, 
Trimipramine drug not metabolized by consider alternative 
CYP2C19 (0). drug not 
metabolized by 
CYP2C19 (0). 
Recommendation strength: S-strong, M-moderate, W-weak, 0-optional 
Adapted with permission from John Wiley and Sons, Inc., from Hicks et al. Clin Pharmacol Ther. 2015 Aug;98(2):127-34. © 2015 American 
Society for Clinical Pharmacology and Therapeutics, and Hicks et al. Clin Pharmacol Ther. 2013 May;93(5):402-8.© 2013 American Society 
for Clinical Pharmacology and Therapeutics. 
current data are unable to provide specific mechanisms. The 
metabolic enzyme activity of CYP2D6 and CYP2C19 has been 
shown to be connected to the plasma concentration of many 
antidepressants, but the clinical response to antidepressants 
does not necessarily have a linear relationship to drug con-
centration; guidelines for CYP2D6 and CYP2C19-based dosing 
are largely proactive and unconfirmed. While ABCBl has 
been examined for its involvement in drug delivery to the 
brain, there is inconclusive evidence on which variations are 
significantly associated with antidepressant response. 
Further studies are needed to identify significant genetic 
pathways. While early trials already indicated possible effica-
cy of genotype-guided drug therapy, further analyses will be 
required to confirm its benefit. Given the high long-term cost 
of treating depression, and further health care costs if treat-
ment fails, even modest improvements in patient response 
could justify the use of genotyping. 
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